4-methoxy-2-oximino-1-indanone | 24623-28-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4-methoxy-2-oximino-1-indanone
• 英文别名: 4-Methoxy-indan-1,2-dione 2-oxime；2-hydroxyimino-4-methoxy-3H-inden-1-one
• CAS: 24623-28-7
• 化学式: C₁₀H₉NO₃
• 分子量: 191.186
• InChiKey: BQQUFJSORJNFGF-UHFFFAOYSA-N

物化性质

• 熔点：
  237-238 °C (decomp)
• 沸点：
  406.3±45.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-methoxy-2-oximino-1-indanone 在 五氯化磷 作用下， 以 正己烷 为溶剂， 生成 2-(氰基甲基)-3-甲氧基苯甲酰氯
  参考文献：
  名称：

  Simchen,G.; Kraemer,W., Chemische Berichte, 1969, vol. 102, p. 3656 - 3665

  摘要：

  DOI：
• 作为产物：
  描述：

  氢化肉桂酸内酯 在 盐酸 、 aluminum (III) chloride 、 亚硝酸丁酯 、 偶氮二甲酸二异丙酯 、 三苯基膦 、 sodium chloride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 7.03h， 生成 4-methoxy-2-oximino-1-indanone
  参考文献：
  名称：

  作为神经保护剂的药用化合物

  摘要：

  本发明公开了一类作为神经保护剂的药用化合物，其为神经元型一氧化氮合酶‑突触后密度蛋白‑95（nNOS‑PSD95）的解耦联剂，其为具有通式（Ⅰ）苯环衍生物或其药学上可接受的盐。本申请进一步公开了该类化合物的制备方法以及其用于预防和治疗受神经元损伤影响引起的疾病的用途。

  公开号：

  CN104045552B

文献信息

• [EN] 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS DE 3-ARYLISOQUINOL-1-ONE 5-SUBSTITUÉE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：CANCER RES INST ROYAL

  公开号：WO2015036759A1

  公开（公告）日：2015-03-19

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc. Formula (I)

  本发明涉及治疗化合物领域。更具体地，本发明涉及某些3-芳基-5-取代-2/-/-异喹啉-1-酮化合物，该化合物在抑制PARP（例如PARP1、TNKS1、TNKS2等）和/或Wnt信号传导方面具有作用。本发明还涉及包含此类化合物的药物组合物，以及使用这些化合物和组合物在体外和体内抑制PARP（例如PARP1、TNKS1、TNKS2等）；抑制Wnt信号传导；治疗通过抑制PARP（例如PARP1、TNKS1、TNKS2等）改善的疾病；治疗通过抑制Wnt信号传导改善的疾病；治疗增生性疾病如癌症等。公式（I）
• Assessment of a potential dopaminergic prodrug moiety in several ring systems
  作者：Joseph G. Cannon、David C. Furlano、Russell G. Dushin、Yu An Chang、Stephen R. Baird、Laila N. Soliman、Jan R. Flynn、John Paul Long、Ranbir K. Bhatnagar

  DOI：10.1021/jm00160a036

  日期：1986.10

  have been incorporated into beta-phenethylamine, 2-aminoindan, and trans-octahydrobenzo[f]quinoline rings. Certain of the 2-aminoindan derivatives displayed pharmacologic properties consistent with their being dopaminergic agonists. The beta-phenethylamine derivative did not show any significant dopamine-like activity. The 7-hydroxy-8-methyloctahydrobenzo[f]quinoline derivative 4a was a moderately potent

  邻羟基/甲基，羟基/羟甲基，羟基/甲酰基和羟基/羧基取代模式（其中一些对2-氨基四氢萘环系统产生多巴胺能激动剂作用）已被结合到β-苯乙胺，2-氨基茚满和反式-八氢苯并[f]喹啉环。2-氨基茚满衍生物中的某些表现出与其多巴胺能激动剂一致的药理特性。β-苯乙胺衍生物未显示任何明显的多巴胺样活性。7-羟基-8-甲基八氢苯并[f]喹啉衍生物4a是中等效力的短效DA2受体拮抗剂。所有的羧酸衍生物都是惰性的。在邻羟基/甲基衍生物中，只有5-羟基-6-甲基-2-氨基四氢萘衍生物显示出与多巴胺能前药一致的药理特性。结论是5-羟基-6-甲基-2-（二正丙基氨基）四氢化萘（1a）在结构上对多巴胺能药物是独特的。
• 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE
  申请人：INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)

  公开号：US20160221953A1

  公开（公告）日：2016-08-04

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.

  本发明普遍涉及治疗化合物领域。更具体地说，本发明涉及某些3-芳基-5-取代-2/-/-异喹啉-1-酮化合物，其可以抑制PARP（例如，PARP1，TNKS1，TNKS2等）和/或Wnt信号。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物，在体内外中抑制PARP（例如，PARP1，TNKS1，TNKS2等）；抑制Wnt信号；治疗通过抑制PARP（例如，PARP1，TNKS1，TNKS2等）改善的疾病；治疗通过抑制Wnt信号改善的疾病；治疗增殖性疾病，如癌症等。
• HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity
  作者：Denis R. St. Laurent、Michael H. Serrano-Wu、Makonen Belema、Min Ding、Hua Fang、Min Gao、Jason T. Goodrich、Rudolph G. Krause、Julie A. Lemm、Mengping Liu、Omar D. Lopez、Van N. Nguyen、Peter T. Nower、Donald R. O’Boyle、Bradley C. Pearce、Jeffrey L. Romine、Lourdes Valera、Jin-Hua Sun、Ying-Kai Wang、Fukang Yang、Xuejie Yang、Nicholas A. Meanwell、Lawrence B. Snyder

  DOI：10.1021/jm301796k

  日期：2014.3.13

  A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and genotype 1b (G-1b) replicon inhibition and selectivity against BVDV and cytotoxicity. SAR emerging from an examination of the prolinamide cap region revealed 11 to be a selective HCV NS5A inhibitor exhibiting submicromolar potency against both G-1a and G-1b replicons. Additional structural refinements resulted in the identification of 30 as a potent, dual G-1a/1b HCV NS5A inhibitor.
• Dopamine D₃ Receptor Antagonists. 1. Synthesis and Structure−Activity Relationships of 5,6-Dimethoxy-<i>N</i>-alkyl- and <i>N</i>-Alkylaryl-Substituted 2-Aminoindans
  作者：Susanne R. Haadsma-Svensson、Kerry A. Cleek、Dac M. Dinh、J. Neil Duncan、Christopher L. Haber、Rita M. Huff、Mary E. Lajiness、Nanette F. Nichols、Martin W. Smith、Kjell A. Svensson、Matt J. Zaya、Arvid Carlsson、Chiu-Hong Lin

  DOI：10.1021/jm010145w

  日期：2001.12.1

  5,6-Dimethoxy-2-(N-dipropyl)-aminoindan (3, PNU-99194A) was found to be a selective dopamine D-3 receptor antagonist with potential antipsychotic properties in animal models. To investigate the effects of nitrogen substitution on structure-activity relationships, a series of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans were synthesized and evaluated in vitro for binding affinity and metabolic stability. The results indicate that substitution at the amine nitrogen of the 2-aminoindans is fairly limited to the di-N-propyl group in order to achieve selective D-3 antagonists. Thus, combinations of various alkyl groups were generally inactive at the D-3 receptor. Although substitution with an N-alkylaryl or N-alkylheteroaryl group yields compounds with potent D-3 binding affinity, the D-2 affinity is also enhanced, resulting in a less than 4-fold preference for the D-3 receptor site, and no improvements in metabolic stability were noted. A large-scale synthesis of the D-3 antagonist 3 has been developed that has proven to be reproducible with few purification steps. The improvements include the use of 3,4-dimethoxybenzaldehyde as a low-cost starting material to provide the desired 5,6-dimethoxy-1-indanone 5c in good overall yield (65%) and the formation of a soluble silyl oxime 17 that was reduced efficiently with BH3. Me2S. The resulting amino alcohol was alkylated and then deoxygenated using a Lewis acid and Et3SiH to give the desired product 3 in good overall yield of (similar to 65%) from the indanone 5c.